Williams Brinkley Ruth
Known title: DirectorCIK: 0001344381
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Natera Named to TIME Best Inventions, Gets PT Hikes. Natera's Signatera test was named to TIME's Best Inventions of 2026, highlighting its clinical relevance. The company also announced a collaboration with TransCode Therapeutics for a colorectal cancer trial. Morgan Stanley and TD Cowen recently raised their price targets, reflecting strong analyst confidence in the stock's trajectory.
Transaction History
| TVTX | ▲ Buy | Grant | 4,000 | $0 | 5/19/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 86 | — | 4/24/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 73 | — | 1/30/2026 | View on chart |
| NTRA | ▲ Buy | Grant | 97 | — | 10/31/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 112 | — | 7/25/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 2,143 | — | 6/27/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/15/2025 | View on chart |
| NTRA | ▲ Buy | Grant | 2,964 | — | 6/28/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,500 | $0 | 5/8/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 4,500 | $0 | 5/17/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 3,000 | $0 | 5/11/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 5,250 | $0 | 9/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.